Trial Profile
A trial comparing the efficacy and safety of two different titration algorithms for insulin degludec/insulin aspart in subjects with type 2 diabetes mellitus previously treated with insulin glargine
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 05 Apr 2018
Price :
$35
*
At a glance
- Drugs Insulin degludec/insulin aspart (Primary)
- Indications Type 2 diabetes mellitus
- Focus Registrational; Therapeutic Use
- Acronyms BOOST; BOOST: SIMPLE vs. STEPWISE
- Sponsors Novo Nordisk
- 01 Aug 2013 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
- 06 Feb 2013 Planned End Date changed from 1 Jul 2013 to 1 Aug 2013 as reported by ClinicalTrials.gov.
- 06 Feb 2013 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.